Likelihood of Approval and Phase Transition Success Rate Model – Purinostat Mesylate in Unspecified B-Cell Lymphomas
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Purinostat Mesylate in Unspecified B-Cell Lymphomas report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Purinostat Mesylate in Unspecified B-Cell Lymphomas Drug Details:
Purinostat mesylate (12l) is under development for the treatment of hematological tumors including but not limited to B-cell lymphoma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), cutaneous T-cell lymphoma, NK/T-cell lymphoma neoplasm (nasal type), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), multiple myeloma, B-cell acute Leukemia, triple-negative Breast cancer, colorectal cancer, urothelial cancer, HER2 negative breast cancer, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, esophageal cancer, cervical cancer, hepatocellular carcinoma, renal cell carcinoma,T-cell lymphoma, T-cell acute leukemia after standard regimen therapy, solid tumors including lung cancer, breast cancer, colon cancer etc. It is a dual inhibitor of serine/threonine protein kinase mTOR and histone deacetylase 1 (HDAC1). The drug candidate is designed and synthesized using pyrimidine-pyrazolyl pharmacophore. It is administered through intravenous route.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Purinostat Mesylate LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports